(3-methyl-pyridin-4-yl)-acetic acid methyl ester | 59256-90-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (3-methyl-pyridin-4-yl)-acetic acid methyl ester
• 英文别名: (3-Methylpyrid-4-yl)-essigsaeuremethylester；Methyl 2-(3-methylpyridin-4-yl)acetate
• CAS: 59256-90-5
• 化学式: C₉H₁₁NO₂
• 分子量: 165.192
• InChiKey: DSYJZEXOJOKCLM-UHFFFAOYSA-N

物化性质

• 沸点：
  93-95 °C(Press: 0.2 Torr)
• 密度：
  1.088±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3-methyl-pyridin-4-yl)-acetic acid methyl ester 在 六甲基磷酰三胺 、 lithium hydroxide 、 四丁基氟化铵 、 双(三甲基硅烷基)氨基钾 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 25.5h， 生成 2-{4-[1-(3,4-Bis-difluoromethoxy-phenyl)-2-(3-methyl-pyridin-4-yl)-ethyl]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol
  参考文献：
  名称：

  Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters

  摘要：

  A detailed SAR study directed toward the optimization of pharmacokinetic parameters for analogues of L-791,943 is reported. The introduction of a soft metabolic site on this structure permitted the identification of L-826,141 as a potent phosphodiesterase type 4 (PDE4) inhibitor that is well absorbed and that presents a shorter half-life than L-791,943 in a variety of animal species. The efficacy of L-826,141 is also demonstrated in different in vivo models. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00615-7
• 作为产物：
  描述：

  3,4-二甲基吡啶 、 碳酸二甲酯 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 以75%的产率得到(3-methyl-pyridin-4-yl)-acetic acid methyl ester
  参考文献：
  名称：

  Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters

  摘要：

  A detailed SAR study directed toward the optimization of pharmacokinetic parameters for analogues of L-791,943 is reported. The introduction of a soft metabolic site on this structure permitted the identification of L-826,141 as a potent phosphodiesterase type 4 (PDE4) inhibitor that is well absorbed and that presents a shorter half-life than L-791,943 in a variety of animal species. The efficacy of L-826,141 is also demonstrated in different in vivo models. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00615-7

文献信息

• CHIRAL CONTROL
  申请人：WAVE LIFE SCIENCES PTE. LTD.

  公开号：US20150211006A1

  公开（公告）日：2015-07-30

  The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.

  本发明涉及手性控制的寡核苷酸、手性控制的寡核苷酸组合物以及其制备和使用方法。本发明特别涵盖了鉴定以前制备手性寡核苷酸方法中某些问题的来源，包括禁止制备完全手性控制的组合物，特别是包含多种寡核苷酸类型的组合物。在某些实施例中，本发明提供了手性控制的寡核苷酸组合物。在某些实施例中，本发明提供了制备手性控制的寡核苷酸和手性控制的寡核苷酸组合物的方法。
• Modification of the pyridine moiety of non-peptidyl indole GnRH receptor antagonists
  作者：Joseph P Simeone、Robert L Bugianesi、Mitree M Ponpipom、Yi Tien Yang、Jane-Ling Lo、Joel B Yudkovitz、Jisong Cui、George R Mount、Rena Ning Ren、Mellissa Creighton、An-Hua Mao、Stella H Vincent、Kang Cheng、Mark T Goulet

  DOI：10.1016/s0960-894x(02)00751-5

  日期：2002.11

  The synthesis of a number of indole GnRH antagonists is described. Oxidation of the pyridine ring nitrogen, combined with alkylation at the two position, led to a compound with an excellent in vitro activity profile as well as oral bioavailability in both rats and dogs. (C) 2002 Elsevier Science Ltd. All rights reserved.
• BOSCH J.; CANALS J.; GRANADOS R., AN. QUIM. REAL SOC. ESP. FIS. Y QUIM. <ANQU-BU>, 1975, 71, NO 9-10, 835-8+
  作者：BOSCH J.、 CANALS J.、 GRANADOS R.

  DOI：——

  日期：——
• [EN] CHIRAL CONTROL<br/>[FR] CONTRÔLE CHIRAL
  申请人：ONTORII INC

  公开号：WO2014012081A2

  公开（公告）日：2014-01-16

  The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same.
• [EN] OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF<br/>[FR] COMPOSITIONS D'OLIGONUCLÉOTIDES ET PROCÉDÉS ASSOCIÉS
  申请人：WAVE LIFE SCIENCES LTD

  公开号：WO2017192664A1

  公开（公告）日：2017-11-09

  Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.